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Abstract
Viscum album (VA) preparations are extensively used as complementary therapy in cancer and are shown to exert anti-
tumor activities which involve the cytotoxic properties, induction of apoptosis, inhibition of angiogenesis and several other
immunomodulatory mechanisms. In addition to their application in cancer therapy, VA preparations have also been
successfully utilized in the treatment of several inflammatory pathologies. Owing to the intricate association of
inflammation and cancer and in view of the fact that several anti-tumor phytotherapeutics also exert a potent anti-
inflammatory effect, we hypothesized that VA exerts an anti-inflammatory effect that is responsible for its therapeutic
benefit. Since, inflammatory cytokine-induced cyclo-oxygenase-2 (COX-2) and prostaglandin E2 (PGE2) play a critical role in
the pathogenesis of inflammatory diseases, we investigated the anti-inflammatory effect of VA on regulation of cyclo-
oxygenase expression and PGE2 biosynthesis by using human lung adenocarcinoma cells (A549 cells) as a model. A549 cells
were stimulated with IL-1b and treated with VA preparation (VA Qu Spez) for 18 hours. PGE2 was analysed in the culture
supernatants by enzyme immunoassay. Expression of COX-2 and COX-1 proteins was analyzed by immunoblotting and the
expression of COX-2 mRNA was assessed by semi-quantitative RT-PCR. We found that VA Qu Spez inhibit the secretion of IL-
1b-induced PGE2 in a dose-dependent manner. Further, we also show that this inhibitory action was associated with a
reduced expression of COX-2 without modulating the COX-1 expression. Together these results demonstrate a novel anti-
inflammatory mechanism of action of VA preparations wherein VA exerts an anti-inflammatory effect by inhibiting cytokine-
induced PGE2 via selective inhibition of COX-2.
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Introduction
VA preparations are standardized aqueous extracts of Viscum
album L. (commonly known as European mistletoe, a semi-parasite
that grows on different host trees), composed mainly of mistletoe
lectins and viscotoxins [1–3] and several other biologically active
molecules like flavonoids, several enzymes, peptides (such as
viscumamide), amino acids, thiols, amines, polysaccharides,
cyclitoles, lipids, phytosterols, triterpines, phenylpropanes and
minerals [4]. Based on the host tree and the method of extraction,
currently at least three VA preparations are available for
therapeutic application: VA Qu Spez (oak tree), VA P (pini) and
VA M (mali). For a long time, VA preparations have been used as
complementary therapy for several types of cancer, mainly in
Europe and also to some extent in other parts of the world [5,6].
Therapeutic benefit of VA preparations when utilized along with
surgery, chemotherapy or radiotherapy contributes to the overall
improvement in the quality of life in cancer patients [7–10]. In
addition, VA preparations are also implicated as conventional
phytotherapeutics in the treatment of several conditions associated
with the nervous system abnormalities, allergic reactions, and
immuno-inflammatory disorders [11–16].
Despite their use for the past several decades, the precise
mechanisms associated with anti-tumoral effects of VA are not
completely understood. Several mutually non-exclusive mecha-
nisms have been proposed, which include induction of apoptosis
and cytotoxicity in tumor cells and inhibition of process of
angiogenesis [10–22]. VA preparations also exert several immuno-
stimulatory mechanisms by interacting with the cellular and
humoral compartments of the immune system thus potentiating an
anti-tumor immune response [22–30]. However, the mechanisms
of action of Viscum album underlying their therapeutic benefits in
inflammatory pathologies are yet to be explored. In this study, we
therefore investigated the anti-inflammatory mechanisms of VA
preparations.
Inflammation is a basal physiological phenomenon that occurs
as a complex set of responses to an infectious agent or to a tissue
injury so as to eliminate the causative agent and to initiate the
healing process. It is a physiopathological symptom in a variety of
conditions of infectious, autoimmune or of tumoral origin.
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immune cells such as endothelial cells and fibroblasts with
inflammatory stimulus induces the production of several molecular
mediators such as cytokines, chemokines, bioactive amines,
eicosanoids, and products of proteolytic cascades, such as
bradykinin [31–37]. These inflammatory mediators acts on
various target tissues and exert changes in their homeostatic
functions and therefore inflammation has to be kept in check
which can be acieved by various anti-inflammatory agents
including steroids, non-steroidal antiinflammatory agents, intrave-
nousimmunoglobulins, immunosuppressor cells, neutralizing
monoclonal antibodies to inflammatory cytokines [38–45].
PGE2, a derivative of eicosanoids, plays an important role as
molecular mediator of inflammatory response. Overproduction of
PGE2 is observed in many of the human pathologies associated
with inflammation and pro-tumoral condition [46–49]. PGE2 is
synthesized by cyclo-oxygenases, COX-1 (expressed constitutively)
and COX-2 (induced in response to inflammatory stimulus).
COX-2 is transcriptionaly activated and over expressed in
response to many pro-inflammatory stimuli like IL-1b, IFN-c,
TNF-a and also pathogen stimuli such as lipopolysaccharides
leading to an enhanced biosynthesis of PGE2 [50]. Therefore,
pharmacological strategies to suppress the COX-2 expression and
PGE2 secretion are of great interest and are being exploited to
develop potent therapeutics to resolve inflammation and several
pro-tumor conditions [51–56]. Indeed, several phytotherapeutics
and plant-derived molecules like curcumin, some of the flavonoids
and polyphenols that have anti-tumor properties also exert anti-
inflammatory activity by down-regulating the expression of COX-
2 and PGE2 biosynthesis [57–67]. Though there are few reports
showing anti-inflammatory activity of certain molecules isolated
from Viscum album, precise mechanisms of action associated with its
therapeutic benefit are yet to be explored [68,69].
Here, we therefore examined the hypothesis that VA exerts
anti-inflammatory effect by interfering with the expression and
biochemical functioning of COX-2 which explains in part, the
mechanisms of actions of VA in several inflammatory pathologies.
Results
Viscum album inhibits cytokine-induced PGE2 secretion
in A549 cells
Human lung adenocarcinoma-derived A549 cells were stimu-
lated with IL-1b for 18 hours in the presence or absence of VA Qu
Spez, a therapeutic preparation of Viscum album that grows on oak
trees. PGE2 was estimated in the culture supernatants by enzyme
immunoassay as explained in Materials and Methods. Inflamma-
tory cytokine IL-1b significantly induced the secretion of PGE2.
We found that VA Qu Spez inhibits the IL-1b-induced PGE2
secretion in a dose-dependent manner (Figure 1). At 50 mg/ml and
100 mg/ml, VA Qu Spez significantly inhibited the secretion of IL-
1b-induced PGE2 secretion.
Viscum album does not inhibit the cytokine-induced
COX-2 mRNA expression
Since the induction of PGE2 by pro-inflammatory cytokines is
known to be associated with the over expression of cox-2 gene, we
analyzed the modulation of mRNA expression of COX-2 by VA.
IL-1b stimulated-A549 cells were harvested following the
treatment with VA Qu Spez and their total cellular RNA was
subjected to reverse transcription and polymerase chain reaction.
Unstimulated cells showed a basal amount of COX-2 mRNA and
it was significantly up-regulated by IL- 1b. However, we found
that VA Qu Spez did not inhibit the cytokine-induced COX-2
mRNA expression (Figure 2). Indeed, no significant change in the
amount of COX-2 mRNA expression was observed even at the
highest concentration of VA (100 mg/ml) used in our experiment.
Viscum album inhibits cytokine-induced COX-2 protein
expression
In order to investigate whether VA-mediated inhibition of the
cytokine-induced PGE2 secretion (Figure 1) correlated with the
reduced level of COX-2 protein, we analyzed the expression of
COX-2 protein in IL-1b-stimulated cells following VA treatment,
by immunoblotting.
Figure 3A depicts a representative blot of the expression pattern
of COX-2 in different culture conditions. Protein expression was
quantified by using densitometry analysis of the blots from 4
independent experiments and relative COX-2 expression normal-
ized to that of b-actin is shown in the histogram (Figure 3B). IL-1b
significantly induced the expression of COX-2 protein. Of interest
and in contrast to mRNA profiles, VA Qu Spez inhibited the IL-
1b-induced expression of COX-2 protein in a dose-dependent
manner. Furthermore, we followed the expression profiles of IL-1b
induced COX-2 in the presence and absence of VA at different
time points (12, 18, 24 and 36 hours) following cytokine
stimulation. Kinetic analysis of COX-2 at two different concen-
trations of VA is shown in Figure 3C. IL-1b induced the
maximum expression of COX-2 at 18 hours and then onwards,
the expression was gradually declined. At 25 mg /ml, VA inhibited
the COX-2 protein expression at 18, 24 and 36 hours and at
50 mg/ml, inhibited COX-2 expression at 18 hours and more
drastically after 24 hours.
Viscum album does not modulate the expression of COX-
1 protein
Since both COX-1 and COX-2 play an important regulatory
role in the biosynthesis of PGE2, we then analysed the effect of VA
on the expression of COX-1 protein, which is a constitutively
expressed isoform of cyclo-oxygenase and is implicated in the
functional homeostasis of the cell. We found that A549 cells
constitutively express COX-1 and the expression of which was not
modified upon treatment of cells with IL-1b (Figure 4A). However,
Figure 1. Inhibition of PGE2 secretion by Viscum album in A549
cells. Cells were treated with IL-1b (10 ng/ml) and increasing
concentrations of VA Qu Spez for 18 hours. PGE2 was analyzed in
culture supernatants by EIA. Results are mean6SEM from 4 indepen-
dent experiments (*p,0.05 versus control cells, **p,0.05 versus cells
treated with IL-1b, analyzed by paired Student-t-test).
doi:10.1371/journal.pone.0026312.g001
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COX-1 protein nor the expression of COX-1 in IL-1b-stimulated
cells (Figure 4A and B). As VA displayed a strong inhibitory effect
on IL-1b-induced COX-2 expression without modulating the
COX-1 level, our results demonstrate that VA selectively inhibits
the expression of COX-2 (Figure 5).
Discussion
The therapeutic benefit of VA in diverse pathologies is
attributed to the method of preparation, the proportion of various
bioactive compounds present within the extracts and also to the
host trees. Several lines of evidence have revealed that VA
preparations exert an anti-tumoral effect because of their ability to
induce apoptosis and to inhibit cell proliferation, providing a
strong basis for their application as complementary therapy in
cancer. However, successful utilization of these preparations in the
treatment of certain inflammatory pathologies raises several
questions related to their mechanisms of action. With the aim of
understanding the role of VA in modulating the immuno-
inflammatory response, we analysed the effect of VA on the
PGE2 axis and its regulation at cyclo-oxygenase level.
Cyclo-oxygenases are the regulatory enzymes of PGE2
biosynthetic pathway which catalyse the rate limiting step. They
convert the free arachidonic acid in the cell cytosol obtained upon
degradation of membrane phospholipids into prostaglandin H2
(PGH2), an active precursor for the synthesis of various
prostanoids. Among the isoforms of cyclo-oxygenases, COX-1 is
constitutively expressed in the cells whereas COX-2 is induced in
response to inflammatory stimuli and contributes majorly to the
induction of PGE2 [70]. PGE2 is a molecular mediator of several
homeostatic functions including those of gastric mucosa and
vascular endothelium [71]. However, it also exerts potent pro-
inflammatory effects including the induction fever and pain.
Figure 2. Effect of VA Q Spez on IL-1b-induced COX-2
transcription. Total cellular RNA was isolated from A549 cells that
were cultured either in medium alone or stimulated with IL-1b (10 ng/
ml) with or without various concentrations of VA for 18 hours. mRNA
expression of COX-2 was analyzed by semi quantitative RT-PCR using
COX-2-specific primers. Amplification of a house keeping gene GAPDH
is used as an internal control. (A) PCR products were separated on 1%
agarose gel and a representative gel picture is shown. (B) Relative
expression (mean 6 SEM) of COX-2 mRNA from six independent
experiments as quantified by densitometry (ratio of density of COX-2:
that of GAPDH). * P,0.05 analyzed by paired Student-t-test, ns refers to
non-significant, compared to IL-1b stimulated cells.
doi:10.1371/journal.pone.0026312.g002
Figure 3. Inhibition of cytokine-induced COX-2 protein expres-
sion by Viscum album in A549 cells. A549 cells were either cultured
in medium alone or treated with IL-1b (10 ng/ml) with or without
increasing concentration of VA Qu Spez for 18 hours. Using 20 mgo f
total cellular protein, expression of COX-2 was analyzed by western
blotting. A. A representative western-blot depicting the effect of VA on
expression of IL-1b-induced COX-2. B. Relative expression (mean 6
SEM) of COX-2 protein from four independent experiments as
quantified by densitometry (ratio of density of COX-2: that of b-actin).
*P,0.05 versus control cells and ** p,0.05 versus IL-1b-stimulated cells
as analyzed by paired Student-t-test. C. Kinetics of COX-2 protein
expression upon treatment of A549 cells with various doses of VA. The
cells were either cultured in medium alone or stimulated with IL-1b with
our without VA for 12, 18, 24 and 36 hours. Expression of COX-2 protein
was analyzed by western blotting and relative expression of COX-2
protein was quantified by densitometry (ratio of density of COX-2: that
of b-actin). Results are representative of two experiments.
doi:10.1371/journal.pone.0026312.g003
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stimuli and correlates with the severity of certain infectious and
inflammatory conditions [46–49]. PGE2 exerts autocrine and
paracrine actions on the target cells and can induce pro-
inflammatory reactions. Cyclo-oxygenases have thus constituted
attractive targets for designing the anti-inflammatory molecules
such as non-steroid anti-inflammatory drugs (NSAID) and for the
conception of novel phytotherapeutics [51,52].
Our results demonstrate that the anti-inflammatory function of
VA implicates inhibition of IL-1b-induced PGE2 biosynthesis. In
order to understand the mechanisms underlying the VA-mediated
inhibition of PGE2 secretion, we analyzed the expression pattern
of cytokine-induced COX-2 in the presence of VA. RT-PCR
results confirmed that IL-1b induces the expression of COX-2
mRNA while VA does not modulate this cytokine-induced
expression of COX-2 mRNA. On the contrary, VA significantly
inhibited COX-2 protein expression induced by IL-1b. These
results suggest that VA exerts a post-transcriptional regulatory
effect on COX-2 expression [72].
The effect of VA was not restricted to IL-1b-induced COX-2
alone. VA also showed an inhibitory effect on IFN-c and
TNF-a-induced COX-2 expression (data not shown). Since,
inflammation is a consequence of signaling of various inflamma-
tory cytokines released by innate and adaptive immune cells,
endothelial cells and epithelial cells, our results thus indicate that
suppression of COX-2 by VA is not restricted to an inflammation
created by a particular cytokine rather VA inhibits COX-2
expression mediated by a wide range of cytokines. This inhibitory
effect of VA at the protein expression level suggests its probable
action in interfering with the process of translation resulting in the
quantitative reduction of the protein. Further, kinetic analysis of
COX-2 expression induced by IL-1b showed a typical time-
dependant increase in protein expression reaching a maximum at
18 hours followed by a decline at later time points. At each time
point, treatment of the cells with VA resulted in the reduced
expression of COX-2 induced by IL-1b. This reduction in the
presence of VA was more pronounced at 24 and 36 hours as
compared to cells treated with IL-1b alone indicating a possible
effect of VA on protein degradation. Together, modulation of
COX-2 by VA strongly favours the role of VA as an anti-
inflammatory therapeutic.
From the viewpoint of an anti-inflammatory therapeutic,
inhibition of PGE2 synthesis by acting at the level of cyclo-
oxygenases exposes a major concern of reducing the homeostatic
levels of PGE2 because of the simultaneous inhibition of COX-1
and COX-2. Owing to the structural and functional homology
between the COX-1 and COX-2, most of the NSAID which are
synthetically designed to inhibit the enzymatic activity of COX-2
also inhibit COX-1, thereby affecting the overall level of PGE2
and are therefore known to cause several severe side effects [73].
Thus, specific inhibitors of COX-2 represent attractive therapeutic
alternatives for several inflammatory pathologies [51]. Interest-
ingly, in our study, at all the concentrations of VA which inhibited
COX-2, we did not observe any change in the expression of COX-
1, irrespective of a robust stimulation by IL-1b. These findings
suggest a strong selectivity in anti-inflammatory mechanism of VA
by inhibiting COX-2 expression.
Long-term side effects of NSAID in various pathological
conditions and the increasing body of evidence for anti-
inflammatory activity of plant-derived molecules together encour-
age the conception of phytotherapeutics as potent alternatives to
classical anti-inflammatory drugs [73,74]. Several clinical studies
Figure 4. Effect of Viscum album on COX-1 expression in A549
cells. A and B. A549 cells were treated with increasing concentrations
of VA Qu Spez in presence of IL-1b (10 ng/ml) for 18 hours. Protein
expression of COX-1 was analyzed by western blot. A representative
western-blot depicting the effect of VA on COX-1 expression under IL-
1b-stimulated culture conditions (A). Relative expression (mean 6 SEM)
of COX-1 protein from three independent experiments as quantified by
densitometry (ratio of density of COX-1: that of b-actin). ns, non-
significant (B). C. Cells were cultured either in medium alone or treated
with increasing concentrations of VA Qu Spez without IL-1b for
18 hours. 20 mg of total cellular protein was separated by 10% SDS-
PAGE followed by western blotting to analyze the expression of COX-1.
Results are representative of two experiments.
doi:10.1371/journal.pone.0026312.g004
Figure 5. Selective inhibition of COX-2 expression by Viscum
album. Quantitative comparison between expression of COX-1 and
COX-2 proteins as revealed by western blot. Protein expression was
quantified by densitometry and expressed as percentage protein
expression normalized to that in cells stimulated with IL-1b. Results
(mean 6 SEM) obtained from 3 independent experiments are
presented. * P,0.05 versus control cells for COX-2 and ** p,0.05
versus IL-1b-stimulated cells for COX-2 as analyzed by paired Student-t-
test. The values for COX-1 are non-significant.
doi:10.1371/journal.pone.0026312.g005
Viscum album and COX-2
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inhibiting COX-2 that are as efficient as synthetic COX-2-specific
antagonists (rofecoxib and celecoxib) in rescuing from both acute
and chronic inflammatory conditions and some of these plant-
derivatives are superior to synthetic molecules in their anti-
inflammatory and analgesic effect [74,75]. With the growing
interest of promising new generation anti-inflammatory therapeu-
tics, exploring and characterizing the novel phytotherapeutics with
strong selectivity towards COX-2 are of great value. Together, our
results demonstrate that VA exerts an anti-inflammatory effect by
interfering with the cytokine-induced PGE2 biosynthesis through a
selective inhibition of COX-2 protein suggesting its beneficial role
with minimal side effects. These results are relevant in under-
standing the mechanism of action of VA and may provide an
insight for further exploration of anti-inflammatory mechanisms of
VA and other plant-derived molecules in diverse pathologies.
Materials and Methods
Viscum album preparations
VA Qu Spez was a kind gift from Weleda AG (Arlesheim,
Switzerland). VA Qu Spez is a therapeutic preparation of Viscum
album growing on oak trees and is obtained as an isotonic solution
of 5 mg/ml and 10 mg/ml formulated in 0.9% NaCl. It is free
from endotoxin and contains the standardized levels of mistletoe
lectins (0.375 ng/ml) and viscotoxins (0.12 ng/ml).
Culture of A549 cells
Human lung adenocarcinoma cell line A549 was a kind gift
from Dr. Maria Castedo-Delrieu, Institute Gustave Roussy,
Villejuif, France. A549 cells were grown in 75 cm
2 culture flasks
in Dulbecco’s modified Eagle’s medium (DMEM) F-12, GIBCOH,
BRL Life Technologies, Grand Island, NY, USA)) supplemented
with 10% fetal calf serum and 50 U/ml penicillin and 50 mg/ml of
streptomycin (GIBCOH, BRL, Cergy Pontoise, France). Cells are
incubated at 37uC with 5% CO2 in humidified atmosphere to
obtain the cells of about 80–90% confluence and used for all
experiments.
Induction of COX-2 and treatment with VA Qu Spez
Cells grown in complete medium were harvested by tripsinisa-
tion using 0.5% trypsin (Biological Industries, Kibbutz Beit
Haemek, Israel) and are seeded in six well culture plates (1610
6
cells per well), and incubated at 37uC till they reach confluence of
80–90%. Wells containing the adherent A549 are then replenished
with the complete medium containing recombinant human IL-1b
(10 ng/ml) (Immuno Tools, Friesoythe, Germany) in the presence
and absence of VA Qu Spez and incubated for 18 hours at 37uC
and 5% CO2. After 18 hours of incubation culture supernatants
were collected and used for the estimation of PGE2 and cells are
used for estimating the mRNA and protein levels of COX-2/
COX-1.
Enzyme immunoassay for PGE2
PGE2 is estimated in the culture supernatants by using
competitive enzyme immunoassay (EIA) kit (Cayman Chemicals
Co, Ann Arbor, MI, USA) according to the manufacturer’s
instructions. Cell free supernatants were analysed for the free
PGE2 released.
Isolation of total RNA and RT-PCR
Total cellular RNA was isolated using RNA isolation kit
(Invitrogen,Life technologies,France)according tothe manufacturers’
instructions. 0.2 mg of total RNA was reverse transcribed to obtain the
cDNA using the Superscript II from (Invitrogen, Life technologies,
France) Semi-quantitative PCR is carried out using COX-2 specific
primers. Amplification of housekeeping gene GAPDH is used as an
internal control. Oligonucleotide primers were purchased from
Eurogentech, France. Sequences of oligonucleotides are as given in
Table 1.
Immunoblotting of COX-2 and COX-1
Following the appropriate treatment, cells were harvested by a
mild tripsinisation and washed with 16phosphate buffered saline.
Cells were lysed using lysis buffer containing 50 mM Tris-HCl
(pH 7.4), 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM
EDTA, 1% NP-40, 1 mM PMSF and 16protease inhibitor cock-
tail (Sigma-Aldrich, Lyon, France). Cells were suspended in the
lysis buffer (100 ml/million cells) and incubated on ice for 30 mins.
Supernatants were collected following the centrifugation at
13200 rpm for 20 mins. Total cellular protein is estimated by
Bradford method and 20 mg of each sample is loaded on SDS
polyacrylamide gel and subjected for electrophoretic migration.
Proteins separated on gel were then transferred on to an activated
PVDF membrane by semi-dry western transfer (2 hours at
50 mA). Non-specific binding of antibodies is blocked by treating
the membrane with 5% non fat milk in tris buffered saline with
tween 20 (TBST-20 mM Tris- HCl (pH 7.4), 137 mM NaCl and
0.1% Tween 20) for 2 hours at room temperature. Membranes
were incubated with primary antibodies diluted according to the
manufactures’ instructions in 5% BSA overnight at 4uC. Following
the three washes with TBST, Blots were then treated with HRP-
conjugated secondary antibodies in 5% BSA (1/4000) for 2 hours
at room temperature. Primary antibodies against human COX-2,
b-Actin, and the HRP labelled secondary antibodies were
procured from Cell Signalling Technology (Ozyme, France).
Human anti-COX-1 is obtained from Santa Cruz Biotechnology
(CA, USA). Blots were washed well with TBST with minimum
three changes for an hour and then revealed using ECL plus
western lightening reagent (Perkin Elmer, Waltham, MA, USA)
according to manufactures’ instructions.
Statistical analysis
Densitometric analysis of the immunoblots was performed using
BIO-1D analysis software. Densitometric values were expressed as
arbitrary units and subjected for statistical analysis by paired
Student-t- test. All the observations are expressed as Mean6SEM.
Graphpad Prism 5.0 is used for all the statistical analysis. P values
less than 0.05 were considered to be statistically significant.
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Table 1. Oligonucleotide primers used in the study.
Human COX-2 (sense) 59-TTCAAATGAGATTGTGGGAAAATTGCT-39
Human COX-2 (antisense) 59-AGATCATCTCTGCCTGAGTATCTT-39
Human GAPDH (sense) 59GAGTCAACGGATTTGGTCGT39
Human GAPDH (antisense) 59TTGATTTTGGAGGGATCTCG-39
doi:10.1371/journal.pone.0026312.t001
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